🇬🇧·4h agoIndustry
27 March 2026Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis BSubmission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials
Publisher
G
GSK RSS
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on gsk.com
Leave the platform to read the original full article on the publisher site.
Source: GSK RSS
Scope: Industry
Related coverage
More related coverage
Hamamatsu (NDP AI)·16h ago
Hamamatsu Photonics and RIKEN sign framework agreement on collaboration
Pharming Group·16h ago
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
Scrip (Informa Intelligence)·1d ago
Anavex Not Giving Up On Alzheimer’s Drug After EU Rejection
The firm looks to have few options left in the European Union after the regulator’s rejection, but s...
Psomagen·1d ago